Antikörper bremst Typ-1-Diabetes-Entwicklung bei Menschen mit hohem Risiko

Kevan C. Herold, Brian N. Bundy, S. Alice Long, Jeffrey A. Bluestone, Linda A. DiMeglio, Matthew J. Dufort, Stephen E. Gitelman, Peter A. Gottlieb, Jeffrey P. Krischer, Peter S. Linsley, Jennifer B. Marks, Wayne Moore, Antoinette Moran, Henry Rodriguez, William E. Russell, Desmond Schatz, Jay S. Skyler, Eva Tsalikian, Diane K. Wherrett, Anette-Gabriele Ziegler, Carla J. Greenbaum, An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes The New England Journal of Medicine. ,vol. 381, pp. 603- 613 ,(2019) , 10.1056/NEJMOA1902226